58,606 Medtronic PLC $MDT Shares Sold by Curated Wealth Partners LLC

Curated Wealth Partners LLC reduced its position in shares of Medtronic PLC (NYSE:MDT) by 86.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,369 shares of the medical technology company’s stock after selling 58,606 shares during the period. Curated Wealth Partners LLC’s holdings in Medtronic were worth $808,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MDT. Arlington Trust Co LLC raised its position in shares of Medtronic by 11.6% in the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after buying an additional 120 shares in the last quarter. Bigelow Investment Advisors LLC boosted its stake in Medtronic by 1.1% during the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock valued at $964,000 after buying an additional 121 shares during the period. Bank & Trust Co boosted its stake in Medtronic by 2.8% during the second quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock valued at $342,000 after buying an additional 121 shares during the period. Grove Bank & Trust grew its position in Medtronic by 1.2% during the third quarter. Grove Bank & Trust now owns 10,564 shares of the medical technology company’s stock worth $912,000 after buying an additional 124 shares in the last quarter. Finally, Integrity Alliance LLC. grew its position in Medtronic by 1.7% during the second quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock worth $578,000 after buying an additional 125 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on MDT shares. Barclays upgraded Medtronic to a “hold” rating in a research note on Wednesday, October 7th. BTIG Research dropped their price target on Medtronic from $100.00 to $99.00 and set a “buy” rating for the company in a research report on Monday. Truist Financial reissued a “hold” rating and set a $99.00 price objective (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Mizuho set a $115.00 price objective on Medtronic in a report on Wednesday, September 2nd. Finally, Bank of America upped their price objective on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Seventeen analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $102.88.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic completed the separation of MiniMed Group, which began trading independently as MiniMed (Nasdaq: MMED). The transaction gives Medtronic a more focused portfolio and could allow both companies to pursue more targeted growth and capital-allocation strategies. Medtronic Completes Separation of MiniMed Group
• Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s Best Inventions of 2026 list. The recognition supports the company’s innovation narrative and may improve visibility for newer products, although it does not directly change near-term earnings. Medtronic Named to TIME Best Inventions List
• Neutral Sentiment: Analysts offered mixed but generally cautious views: Barclays initiated coverage at Equal Weight, while Piper Sandler assigned a Hold rating. These calls suggest analysts see potential from improving sales growth but limited near-term upside after the stock’s recent advance. Barclays Initiates Coverage
• Neutral Sentiment: Recent coverage highlights Medtronic’s stronger fiscal first-quarter results and raised annual outlook, but also notes that the MiniMed separation changes the earnings mix investors are buying. The key question is whether the remaining business can sustain faster growth. Trefis Analysis of Medtronic
• Negative Sentiment: Exchange-offer results and reported ETF sales of approximately $222.5 million indicate meaningful trading and possible short-term selling pressure as investors adjust positions following the MiniMed separation. ETF Sales of Medtronic

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president directly owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.27% of the company’s stock.

Medtronic Stock Performance

Shares of NYSE MDT opened at $95.89 on Friday. The stock’s 50-day moving average is $90.87 and its 200 day moving average is $84.95. The stock has a market cap of $122.66 billion, a price-to-earnings ratio of 23.62, a P/E/G ratio of 2.15 and a beta of 0.55. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, September 25th. Medtronic’s payout ratio is presently 70.94%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.